GDC 0134

Drug Profile

GDC 0134

Alternative Names: GDC0134; RG6000

Latest Information Update: 03 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action DLK-1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 07 Aug 2017 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in United Kingdom (PO) (NCT03237741)
  • 04 Aug 2017 Genentech plans a phase I trial for Amyotrophic lateral sclerosis(In volunteers) in United Kingdom (PO) (NCT03237741)
  • 01 Jan 2016 Phase-I clinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top